Patents by Inventor Olivier Terrier
Olivier Terrier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230210866Abstract: The present invention relates to a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical carrier for its therapeutic use in the prevention and/or treatment of a viral infection caused by the SARS-CoV-2 virus, referred to as COVID-19 disease.Type: ApplicationFiled: March 10, 2021Publication date: July 6, 2023Inventors: Manuel ROSA-CALATRAVA, Olivier TERRIER, Mario Andres PIZZORNO, Aurelien TRAVERSIER, Blandine PADEY, Thomas JULIEN
-
Publication number: 20230075092Abstract: The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.Type: ApplicationFiled: January 12, 2021Publication date: March 9, 2023Inventors: Olivier TERRIER, Manuel ROSA-CALATRAVA, Guy BOIVIN, Mario-Andres PIZZORNO, Blandine PADEY
-
Patent number: 11510896Abstract: The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.Type: GrantFiled: October 20, 2017Date of Patent: November 29, 2022Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Manuel Rosa-Calatrava, Olivier Terrier, Anaïs Proust, Vincent Moules
-
Patent number: 11504424Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.Type: GrantFiled: July 12, 2019Date of Patent: November 22, 2022Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE LAVALInventors: Manuel Rosa-Calatrava, Guy Boivin, Julia Dubois, Mario Andres Pizzorno, Olivier Terrier, Marie-Eve Hamelin, Marie-Helene Cavanagh
-
Publication number: 20220296606Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.Type: ApplicationFiled: May 31, 2022Publication date: September 22, 2022Inventors: Manuel ROSA-CALATRAVA, Olivier TERRIER, Julien TEXTORIS, Guy BOIVIN, Mario PIZZORNO
-
Patent number: 11351180Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.Type: GrantFiled: March 18, 2016Date of Patent: June 7, 2022Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), HOSPICES CIVILS DE LYON, UNIVERSITE LAVALInventors: Manuel Rosa-Calatrava, Olivier Terrier, Julien Textoris, Guy Boivin, Mario Pizzorno
-
Publication number: 20220054618Abstract: The present invention relates to the use of the immortalised cell line ECACC 09070703, deposited on 7 Jul. 2009 at the European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK) under the number 09070703, for the production of a viral vaccine constituted of an attenuated strain derived from a human metapneumovirus.Type: ApplicationFiled: December 12, 2019Publication date: February 24, 2022Inventors: Manuel ROSA-CALATRAVA, Guy BOIVIN, Julia DUBOIS, Mario Andres PIZZORNO, Olivier TERRIER, Aurélien TRAVERSIER
-
Publication number: 20210283239Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.Type: ApplicationFiled: July 12, 2019Publication date: September 16, 2021Inventors: Manuel ROSA-CALATRAVA, Guy BOIVIN, Julia DUBOIS, Mario Andres PIZZORNO, Olivier TERRIER, Marie-Eve HAMELIN, Marie-Helene CAVANAGH
-
Publication number: 20210154205Abstract: The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.Type: ApplicationFiled: May 23, 2019Publication date: May 27, 2021Inventors: Manuel ROSA-CALATRAVA, Olivier TERRIER, Claire NICOLAS DE LAMBALLERIE, Guy BOIVIN, Mario Andres PIZZORNO
-
Publication number: 20190307722Abstract: The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.Type: ApplicationFiled: October 20, 2017Publication date: October 10, 2019Inventors: Manuel ROSA-CALATRAVA, Olivier TERRIER, Anaïs PROUST, Vincent MOULES
-
Publication number: 20180042937Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.Type: ApplicationFiled: March 18, 2016Publication date: February 15, 2018Inventors: Manuel ROSA-CALATRAVA, Olivier TERRIER, Julien TEXTORIS, Guy BOIVIN, Mario PIZZORNO
-
Patent number: 9381238Abstract: The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.Type: GrantFiled: November 4, 2011Date of Patent: July 5, 2016Assignees: UNIVERSITY OF DUNDEE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON I, HOSPICES CIVILS DE LYONInventors: Olivier Terrier, Jean-Christophe Bourdon, Manuel Rosa-Calatrava
-
Patent number: 8926988Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: GrantFiled: November 17, 2009Date of Patent: January 6, 2015Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de LyonInventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Patent number: 8927701Abstract: A variant phylogenetic group of HPIV-2, more particularly a novel variant phylogenetic sub-group of HPIV-2, and a means for diagnosing HPIV-2 which take into account this novel group and this novel sub-group.Type: GrantFiled: July 18, 2008Date of Patent: January 6, 2015Assignees: Centre National de la Recherche Scientifique, Les Hospices Civils de LyonInventors: Bruno Lina, Olivier Terrier, Danielle Françoise Thouvenot
-
Patent number: 8906386Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: GrantFiled: November 17, 2009Date of Patent: December 9, 2014Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de LyonInventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20130315954Abstract: The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.Type: ApplicationFiled: November 4, 2011Publication date: November 28, 2013Applicants: UNIVERSITY OF DUNDEE, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON I, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Olivier Terrier, Jean-Christophe Bourdon, Manuel Rosa-Calatrava
-
Publication number: 20110318355Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: ApplicationFiled: November 17, 2009Publication date: December 29, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20110311541Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: ApplicationFiled: November 17, 2009Publication date: December 22, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20110077170Abstract: A variant phylogenetic group of HPIV-2, more particularly a novel variant phylogenetic sub-group of HPIV-2, and a means for diagnosing HPIV-2 which take into account this novel group and this novel sub-group.Type: ApplicationFiled: July 18, 2008Publication date: March 31, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYONInventors: Bruno Lina, Olivier Terrier, Danielle Francoise Thouvenot